KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Current Leases: 2022-2023

  • Sarepta Therapeutics' Current Leases rose 15.21% to $17.8 million in Q4 2023 from the same period last year, while for Dec 2023 it was $17.8 million, marking a year-over-year increase of 15.21%. This contributed to the annual value of $17.8 million for FY2023, which is 15.21% up from last year.
  • Sarepta Therapeutics' Current Leases amounted to $17.8 million in Q4 2023, which was up 15.21% from $15.5 million recorded in Q4 2022.
  • Sarepta Therapeutics' Current Leases' 5-year high stood at $17.8 million during Q4 2023, with a 5-year trough of $15.5 million in Q4 2022.
  • In the last 2 years, Sarepta Therapeutics' Current Leases had a median value of $16.7 million in 2022 and averaged $16.7 million.
  • Data for Sarepta Therapeutics' Current Leases shows a peak YoY rose of 15.21% (in 2023) over the last 5 years.
  • Over the past 2 years, Sarepta Therapeutics' Current Leases (Quarterly) stood at $15.5 million in 2022, then rose by 15.21% to $17.8 million in 2023.